clinical trial · NCT05033132
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
Cervical CancerBalstilimabBalstilimab + Zalifrelimab
brief summary
This is an open-label, multi-center Phase II clinical trial to assess the efficacy, safety, and pharmacokinetics of Balstilimab (Treatment Arm 1 - monotherapy) or in combination with Zalifrelimab (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy.
started
Oct 1, 2021
primary completion
Dec 30, 2024
completion
Dec 30, 2024
last updated
Mar 28, 2024
official title
An Open-label, Multicenter Phase II Study Evaluating Balstilimab Alone or Balstilimab in Combination With Zalifrelimab in Patients With Advanced Cervical Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol